Carboplatin Articles
Strides Arcolab gets two more cancer generics approved in USA
27 November 2011
Novelos shares slump 82% as pivotal Ph III lung cancer trial fails to meet primary survival endpoint
25 February 2010
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
3 February 2010
Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI
4 January 2010
Seattle Genetics slumps on stopping dacetuzumab Phase IIb diffuse large B-cell lymphoma trial
6 October 2009
Novartis buys generics cancer firm for $1.2B
20 May 2009
Bayer and Onyx halt Nexavar trial
28 April 2009
Amgen/Takeda resume motesanib development
23 February 2009
Peregrine's Ph II breast cancer drug meets first-stage endpoint
16 February 2009
Ph III motesanib trial suspended on deaths
1 December 2008
Japan stock market week to Nov 24, 2008
1 December 2008
OVATURE study gets go-head after interim review
24 November 2008
Peregrine fully enrolled for Ph II NSCLC trial
27 October 2008
Strong mid-stage data on Pfizer's NSCLC drug
22 September 2008
High response rate with TopoTarget's BelCaP
15 September 2008
Oncolytics takes Reolysin into Ph II
8 September 2008
ImClone offers more data from Erbitux trial
8 September 2008
HGS completes enrollment in Ph II mapatumumab trial
1 September 2008
Peregrine initiates Ph II bavituximab study
18 August 2008
Avastin + Herceptin HER2 study initiated
9 June 2008
India's Dabur goes to Fresenius for $220M
28 April 2008
44% bioavailability for Poniard's picoplatin
21 April 2008
Antisoma starts Ph III NSCLC trial, earns $25M
21 April 2008
Reolysin fares well in early carcinoma trial
21 April 2008
Marshall Edwards continues OVATURE trial
17 March 2008
Bayer/Onyx halt Nexavar trial in NSCLC
25 February 2008
UPDATE: Bayer and Onyx halt Nexavar trial in NSCLC
25 February 2008
Peregrine gets Indian OK for Ph II NSCLC trial
28 January 2008
OXiGENE's Zybrestat achieves endpoints in ovarian cancer
7 January 2008
Belinostat shows promise in range of cancer indications
5 November 2007
CT's bis-platinate drugs show activity against resistant tumors
5 November 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Ph II NSCLC ASA404 trial supports earlier findings
17 September 2007
Aranesp has no negative survival impact in SCLC
17 September 2007
Potential of Peregrine's bavituximab and radiation confirmed
10 September 2007
OVATUREtrial.com drug trial web site launched
10 September 2007
TopoTarget initiates Ph II bladder cancer belinostat trial
13 August 2007
CHMP recommends approval of Avastin for NSCLC
30 July 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Preclinical data suggests combo role for Proxinium
23 April 2007
Erbitux increases overall survival in SCCHN
16 April 2007
Combined Reolysin effective in animal cancer models
26 March 2007
Antisoma sees strong Ph II AS1404 data in NSCLC
19 March 2007
Strong data for Avastin may lead to lower dose
5 March 2007
Strong Ph II data for Schering-Plough's Caelyx
5 March 2007
S-P's Caelyx impresses in Ph II cancer trial
26 February 2007
Roche's Avastin is first drug to extend survival in patients with advanced NSCLC beyond one year
22 December 2006
Herceptin/Taxotere improve DF survival
22 December 2006
Nexavar fails in Ph III melanoma study
11 December 2006
PXD101 shows efficacy in Ph Ib cancer study
20 November 2006
Lilly's Almita enters Ph III trial for SCLC
30 October 2006
Genentech's blockbuster Avastin gains new cancer indication; $2B sales predicted in 2007
23 October 2006
US FDA fast-tracks Novelos' NOV-002
14 August 2006
Lilly's Gemzar wins 4th US cancer indication
24 July 2006
Schering AG starts Ph II ZK-EPO trials
29 May 2006
Oxigene's CA4P gets FDA OD
22 May 2006
Enrollment complete in two Ph III Nexavar trials
15 May 2006
Genentech submits Avastin NSCLC sBLA
17 April 2006
Enrollment complete in OXiGENE's CA4P trial
3 April 2006
Bayer/Onyx launch Ph III Nexavar trial
27 February 2006
Dosing starts in TopoTarget/CuraGens' Ph Ib trial of PXD101
19 September 2005
Teva's 2nd-qtr lifted by non-US business
8 August 2005
Mayne gets US appro for multi-dose carboplatin
1 August 2005
Cell Thera's Xyotax sees strong Ph III results
18 July 2005
Promising interim data for Telik's Telcyta
11 July 2005
FDA OKs Spectrum's generic carboplatin
20 June 2005
Bayer/Onyx initiate PH III sorafenib trial
23 May 2005
B-MS 1st-qtr 2005 income down 36%
9 May 2005
Alfacell's Onconase shows activity against NSCLC
25 April 2005
FDA clears Antisoma's Ph II cancer trial
25 April 2005
Japan stock market week to April 4
11 April 2005
Targretin: endpoints missed in NSCLC trials
4 April 2005
APP gets FDA OK for generic Paraplatin
25 October 2004
Spectrum gains first ANDA approval, for ciprofloxacin
20 September 2004
New use for Gemzar OKed in Europe
9 August 2004
Sicor acquisition lifts Teva results
9 August 2004
Encouraging data for Bayer's BAY 43-9006 in melanoma
14 June 2004
B-MS reports 1st-qtr earnings jump 22%
3 May 2004
B-MS announces paraplatin settlement
3 May 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
Aventis' Taxotere and cisplatin improve QoL
28 July 2003
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
